Wegovy

News

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral Wegovy in type 2 diabetes raises as many questions as it answers.

News

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

Novo Nordisk has been criticised by the FDA for a TV ad for the Wegovy pill, which the agency claims makes "false and misleading" claims.

News

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

Novo Nordisk's battered stock enjoyed a reprieve after Hims & Hers abandoned plans to launch a compounded version of the new Wegovy pill.

News

Squeezed by "unprecedented" pricing pressures, Novo Nordisk has forecast a decline in revenues this year.